CLINICAL TRIALS PROFILE FOR TRIAMCINOLONE ACETONIDE

505(b)(2) Clinical Trials for Triamcinolone Acetonide

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials

Trial Type	Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
New Formulation	NCT00071227 ↗	Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders	Completed	National Eye Institute (NEI)	Phase 1	2003-10-15	This study will evaluate the safety and effectiveness of a new formulation of triamcinolone acetonide for the treatment of retinal blood vessel disorders. Triamcinolone is a steroid drug that decreases inflammation and scarring and is routinely used to treat eye inflammation or swelling. The commercially available form of this drug is associated with potentially harmful side effects thought to be due to preservatives in the preparation. This study will use a formulation that does not contain these potentially harmful preservatives. Preliminary findings from other studies suggest that injection of steroids in the eye can reduce retinal thickening and improve vision. However, they may also cause mild discomfort and lead to vision-threatening conditions. The effects of the drug on the conditions under study in this protocol are not known. Patients with the following conditions involving disorders of retinal blood vessels may be eligible for this study: - Choroidal neovascularization associated with age-related macular degeneration (50 years of age and older) - Macular edema associated with retinal vein occlusion (18 years of age and older) - Diabetic macular edema ((18 years of age and older) Participants undergo the following tests and procedures: - Medical history and physical examination - Eye examination to assess visual acuity (eye chart test) and eye pressure, and to examine pupils, lens, retina and eye movements. The pupils will be dilated with drops for this examination. - Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality. - Indocyanine green angiography to identify feeder vessels that may be supplying abnormal blood vessels. This procedure is similar to fluorescein angiography, but uses a green dye and flashes an invisible light. - Optical coherence tomography to measure retinal thickness. This test shines a light into the eye and produces cross-sectional pictures of the retina. These measurements are repeated during the study to determine if retinal thickening is getting better or worse, or staying the same. - Stereoscopic color fundus photography to examine the back of the eye. The pupils are dilated with eye drops to allow examination and photography of the back of the eye. - Triamcinolone acetonide injection to treat the eye. A numbing eye drop, an antibiotic eye drop, and an injected antibiotic are put in the eye before triamcinolone acetonide is injected into the eye's vitreous (jelly-like substance inside the eye). After the injection, the patient lies on his or her back for 30 minutes. An antibiotic eye ointment is used for 2 days following treatment. - Blood tests to measure liver and kidney function. Patients return to the clinic for follow-up visits 1, 4, and 7 days, and 1 month after the first treatment. Patients whose condition does not improve after 3 months do not receive any more injections, but return for eye examinations at least once a year for 3 years. Patients whose condition improves with treatment return for follow-up visits 6 and 9 months after the first injection and then every 6 months for 2 more years. At each visit, a determination is made whether another injection is needed. After each repeat injection, patients return for follow-up visits at 1, 4, and 7 days after the injection.

All Clinical Trials for Triamcinolone Acetonide

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	National Heart, Lung, and Blood Institute (NHLBI)	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000577 ↗	Asthma Clinical Research Network (ACRN)	Withdrawn	Milton S. Hershey Medical Center	Phase 3	1993-09-01	This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00071227 ↗	Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders	Completed	National Eye Institute (NEI)	Phase 1	2003-10-15	This study will evaluate the safety and effectiveness of a new formulation of triamcinolone acetonide for the treatment of retinal blood vessel disorders. Triamcinolone is a steroid drug that decreases inflammation and scarring and is routinely used to treat eye inflammation or swelling. The commercially available form of this drug is associated with potentially harmful side effects thought to be due to preservatives in the preparation. This study will use a formulation that does not contain these potentially harmful preservatives. Preliminary findings from other studies suggest that injection of steroids in the eye can reduce retinal thickening and improve vision. However, they may also cause mild discomfort and lead to vision-threatening conditions. The effects of the drug on the conditions under study in this protocol are not known. Patients with the following conditions involving disorders of retinal blood vessels may be eligible for this study: - Choroidal neovascularization associated with age-related macular degeneration (50 years of age and older) - Macular edema associated with retinal vein occlusion (18 years of age and older) - Diabetic macular edema ((18 years of age and older) Participants undergo the following tests and procedures: - Medical history and physical examination - Eye examination to assess visual acuity (eye chart test) and eye pressure, and to examine pupils, lens, retina and eye movements. The pupils will be dilated with drops for this examination. - Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality. - Indocyanine green angiography to identify feeder vessels that may be supplying abnormal blood vessels. This procedure is similar to fluorescein angiography, but uses a green dye and flashes an invisible light. - Optical coherence tomography to measure retinal thickness. This test shines a light into the eye and produces cross-sectional pictures of the retina. These measurements are repeated during the study to determine if retinal thickening is getting better or worse, or staying the same. - Stereoscopic color fundus photography to examine the back of the eye. The pupils are dilated with eye drops to allow examination and photography of the back of the eye. - Triamcinolone acetonide injection to treat the eye. A numbing eye drop, an antibiotic eye drop, and an injected antibiotic are put in the eye before triamcinolone acetonide is injected into the eye's vitreous (jelly-like substance inside the eye). After the injection, the patient lies on his or her back for 30 minutes. An antibiotic eye ointment is used for 2 days following treatment. - Blood tests to measure liver and kidney function. Patients return to the clinic for follow-up visits 1, 4, and 7 days, and 1 month after the first treatment. Patients whose condition does not improve after 3 months do not receive any more injections, but return for eye examinations at least once a year for 3 years. Patients whose condition improves with treatment return for follow-up visits 6 and 9 months after the first injection and then every 6 months for 2 more years. At each visit, a determination is made whether another injection is needed. After each repeat injection, patients return for follow-up visits at 1, 4, and 7 days after the injection.
NCT00100009 ↗	Triamcinolone Acetonide Plus Laser Therapy to Treat Age-Related Macular Degeneration	Completed	National Eye Institute (NEI)	Phase 3	2004-12-09	This study will test the safety and effectiveness of combining a laser treatment called photodynamic therapy, or PDT, with injections into the eye of the steroid triamcinolone acetonide for treating age-related macular degeneration (AMD). The macula is the part of the retina in the back of the eye that determines central or best vision. AMD can severely impair central vision, affecting a person's ability to read, drive, and carry out daily activities. This vision loss is caused by the formation of abnormal blood vessels behind the retina that leak blood under the macula. PTD stops the growth of these blood vessels and slows the rate of vision loss; however, it has only a temporary effect and does not work in all patients. Furthermore, it may actually cause some swelling and re-growth of blood vessels. Triamcinolone acetonide can help lessen swelling and scarring. Patients 50 years of age and older with AMD may be eligible for this study. Candidates are screened with a medical history, medical evaluation, and eye examinations (see below). Participants are randomly assigned to one of three treatment groups: 1) PDT plus 1 mg TAC-PF; 2) PDT plus 4 mg TAC-PF; or 3) PDT plus sham injection (a syringe with no needle is pressed against the eye). Treatments are given the day the patient enrolls in the study and then every 3 months for 2 years, as long as the therapy is thought beneficial. Patients who must discontinue TAC-PF injections may still be treated with PDT if medically necessary. In addition to treatment, patients undergo the following tests and procedures: - Eye examination: Visual acuity and eye pressure are measured, and the lens, retina, pupils and eye movements are examined. - Fundus photography: Photographs of the back of the eye are taken using a special camera with a bright flash. - Lens photography: Photographs of the lens are taken to look for development of cataracts. - Fluorescein angiography: Pictures of the retina are taken to look for abnormal blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. The retina is photographed using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality. - Optical coherence tomography: This test uses light to produce a 2-dimensional cross-sectional picture of the retina. The patient looks into a machine called an optical coherence tomograph at a pattern of flashing and rotating red and green lights, first with one eye and then the other. - PDT: A needle is placed in an arm vein and a drug called verteporfin (Visudyne® (Registered Trademark)) is infused into the vein over 10 minutes. After 15 minutes, the eye is anesthetized with numbing drops. A special contact lens is then placed on the eye and the laser beam is directed to the eye for 83 seconds. - TAC-PF or injections (for those in the TAC-PF treatment groups): Numbing and anesthetic drops are placed on the surface of the eye before injection of TAC-PF. Another anesthetic is then applied to the lower part of the eye with a cotton swab. After a few minutes, TAC-PF is injected into the vitreous (jelly-like substance inside the eye). Patients receiving sham injections undergo the identical procedure, except a syringe with no needle is pressed against the eye to seem like a real injection. All patients receive antibiotic drops to put in their eye for 2 days after each treatment. Patients return to the clinic anytime from 2 to 7 days after each treatment for a check of vision, eye pressure, and treatment side effects. Patients are seen in the clinic for additional checks at 4 weeks and 4 months after the first treatment.

Clinical Trial Conditions for Triamcinolone Acetonide

Condition Name

Condition Name for Triamcinolone Acetonide
Intervention	Trials
Diabetic Macular Edema	27
Oral Lichen Planus	16
Macular Edema	13
Alopecia Areata	12

Condition MeSH

Condition MeSH for Triamcinolone Acetonide
Intervention	Trials
Macular Edema	58
Edema	44
Osteoarthritis	20
Lichen Planus, Oral	19

Clinical Trial Locations for Triamcinolone Acetonide

Trials by Country

Trials by Country for Triamcinolone Acetonide
Location	Trials
United States	476
Egypt	40
Canada	37
India	33
China	24

Trials by US State

Trials by US State for Triamcinolone Acetonide
Location	Trials
California	34
Texas	28
Pennsylvania	26
New York	25
Florida	25

Clinical Trial Progress for Triamcinolone Acetonide

Clinical Trial Phase

Clinical Trial Phase for Triamcinolone Acetonide
Clinical Trial Phase	Trials
PHASE4	12
PHASE3	5
PHASE2	6

Clinical Trial Status

Clinical Trial Status for Triamcinolone Acetonide
Clinical Trial Phase	Trials
Completed	138
Recruiting	49
Unknown status	37

Clinical Trial Sponsors for Triamcinolone Acetonide

Sponsor Name

Sponsor Name for Triamcinolone Acetonide
Sponsor	Trials
National Eye Institute (NEI)	14
Cairo University	12
Novartis Pharmaceuticals	8

Sponsor Type

Sponsor Type for Triamcinolone Acetonide
Sponsor	Trials
Other	303
Industry	71
NIH	19

Triamcinolone Acetonide: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 28, 2026

What is the current clinical and regulatory footprint for triamcinolone acetonide?

Triamcinolone acetonide (TA) is a long-established corticosteroid marketed in multiple delivery forms (intranasal, inhaled/oral mucosal, injectable). Because the product is already approved, much of the ongoing clinical activity is either (1) line extensions in new indications/administrations, (2) formulation and device optimization trials, or (3) comparative safety/efficacy studies tied to payer and label-maintenance needs.

Commonly observed trial themes in recent years

• Intranasal and rhinitis indications: Comparative efficacy and local tolerability against other intranasal corticosteroids; endpoints typically include symptom score reduction and nasal airflow metrics.
• Intra-articular and periarticular injections: Regimens and injection schedules vs comparator steroids; safety endpoints focus on local reaction rates and systemic steroid exposure proxies.
• Ophthalmic uses (in selected markets): Posterior segment inflammation and post-surgical inflammation trials are typically conducted as label-maintenance or formulation-specific studies.

Implication for an investor or R&D planner

• The clinical pipeline is rarely “first-in-class,” but it can still move market share through formulation differentiation, dose-frequency advantages, and narrow label expansions that improve payer coverage.

What is the market size context for triamcinolone acetonide?

TA participates in multiple corticosteroid markets rather than one single disease category. Economic drivers vary by form:

• Intranasal corticosteroid market (rhinitis): Demand tracks seasonal and perennial allergic rhinitis prevalence, switching behavior after generic entry, and guideline-driven first-line use.
• Injectable steroid market (musculoskeletal and inflammatory conditions): Growth relates to musculoskeletal utilization, osteoarthritis treatment patterns, and procedure volume.
• Ophthalmic steroid market (where locally authorized): Utilization depends on cataract/post-operative inflammation and noninfectious uveitis treatment patterns.

Commercial reality

• In many jurisdictions, TA faces generic competition and therapeutic class substitution, compressing pricing but supporting stable unit demand.
• Value growth typically comes from brand protection strategies in specific presentations, health-system contracting, and any measurable adherence or safety advantages in competitive switching.

Where does TA compete, and how does competition shape pricing?

TA competes primarily against other corticosteroids in the same delivery modality:

• Intranasal: Competes with other intranasal steroids (including fluticasone, budesonide, mometasone depending on country). Competitive differentiation tends to center on dosing frequency, device usability, and side-effect profile (epistaxis risk, nasal irritation).
• Injectable: Competes with alternative corticosteroids by injection and by physician preference, with safety and familiarity influencing uptake.
• Ophthalmic (if marketed locally in relevant form): Competes within ophthalmic steroid portfolios, where duration of action and post-surgical protocols matter.

Market mechanism

• When generics dominate, TA pricing typically declines toward class averages. Companies that win share do it via:
  • Contracting and tender placement
  • Formulation/device upgrades that reduce administration burden
  • Targeted label language that supports reimbursement

What does the pipeline structure look like for TA versus new steroid candidates?

TA’s pipeline profile contrasts with newer corticosteroid entrants in two ways:

1. Lower probability of blockbuster-scale new mechanisms: TA is already mechanistically established.
2. Higher probability of measurable incremental wins: formulation, dosing convenience, and tolerability can still drive share.

As a result, clinical trial value for TA is often judged on:

• Target population response rates in the label-relevant endpoints
• Comparative local tolerability
• Device performance (injection site pain, spray plume characteristics, adherence metrics)

What is the clinical trials update for triamcinolone acetonide?

A current “update” requires pulling specific trial records (IDs, statuses, and results) from registries. Without registry-specific inputs, the only accurate description is structural: TA trials are ongoing primarily as line extensions and formulation comparisons across the modalities above. The commercial and reimbursement posture of TA strongly favors trials with payers and formularies in mind (comparative endpoints and safety signal quantification).

How to interpret TA trial activity

• If the trial is comparative (TA vs another corticosteroid), it typically informs formulary placement.
• If the trial is formulation-specific (particle size, vehicle, device, suspension stability), it typically informs switching behavior and contracting.
• If the trial is regimen-specific (dose reduction, fewer injections, dosing interval), it targets cost-per-treatment and adherence outcomes.

What are market drivers by delivery form?

Intranasal triamcinolone acetonide

Key drivers

• Seasonal allergy prevalence and long-term adherence to intranasal steroids
• Physician preference for steroid type and device
• Payer adoption of guideline-recommended first-line intranasal therapy
• Generic substitution pressure

Key risks

• Epistaxis and local irritation intolerance leading to discontinuation
• Strong competitive class substitutes with similar efficacy profiles

Injectable triamcinolone acetonide (in inflammatory and musculoskeletal settings)

Key drivers

• Procedure volume in primary care, orthopedics, rheumatology, and pain management
• Chronic disease burden (osteoarthritis and inflammatory states)
• Short-term response demand that fits injectable steroids

Key risks

• Safety perceptions and injection-frequency constraints
• Movement toward alternative non-steroidal or disease-modifying approaches in some segments

Ophthalmic triamcinolone acetonide (where authorized)

Key drivers

• Post-surgical inflammation protocols
• Noninfectious inflammation demand

Key risks

• Competing ophthalmic steroid technologies and sustained-release formats
• Reimbursement and pathway constraints

What is the market projection for triamcinolone acetonide through the mid-term?

Because TA is entrenched and widely genericized, projection is driven less by demand creation and more by unit retention and share shifts within class.

Projection logic used for established multi-form generics

• Stable-to-moderate unit growth from disease prevalence growth and procedure volume
• Pricing compression through generic competition and tender-driven procurement
• Value stabilization if select branded or differentiated presentations maintain stronger net pricing
• Incremental value uplift only if a formulation or label update improves payer access

Mid-term base case

• Moderate revenue growth in absolute terms can occur if unit volume grows faster than price declines in key geographies and if branded/differentiated presentations persist.
• Exiting the “race to the bottom” is hard for commoditized presentations, so ROI typically relies on differentiation and contracting leverage.

What business decisions does the TA profile support?

TA is best approached as a portfolio and execution game, not a discovery game.

Commercial strategy

• Target markets where differentiated presentation or device quality materially affects switching or adherence
• Prioritize formulary access through comparative tolerability and outcome data
• Use tenders and hospital contracting to lock in utilization

R&D strategy

• Focus trial design on endpoints that map to payer and guideline decisions:
  • Symptom reduction and time to meaningful improvement (rhinitis)
  • Local tolerability and systemic exposure proxies where relevant
  • Device performance and patient usability outcomes
• Choose formulation/regimen work that produces measurable adherence or administration benefits

Key Takeaways

• Triamcinolone acetonide remains a multi-modality corticosteroid with ongoing clinical activity mainly tied to line extensions, formulation/device optimization, and comparative studies.
• The market is structurally stable in unit terms but typically price-compressed under generic competition; value growth depends on differentiated presentations and contracting.
• Competitive advantage is most often realized through device and formulation differentiation, comparative tolerability, and label wording that supports reimbursement.
• Mid-term growth is expected to be moderate, driven by utilization persistence and selective share gains rather than new-mechanism demand expansion.

FAQs

1) Is triamcinolone acetonide still generating new clinical evidence?

Yes. Ongoing studies generally target formulation, device, regimen, and comparative positioning rather than introducing a new mechanism of action.

2) What endpoints matter most for intranasal TA trials?

Intranasal symptom scores, time to improvement, and local tolerability measures (such as irritation and epistaxis rates), aligned to guideline and formulary decision-making.

3) How does generic competition affect TA market projections?

It compresses pricing and shifts growth from revenue per unit to volume retention and selective share gains in differentiated presentations.

4) Where can TA still win market share?

In contracts where comparative tolerability, dosing convenience, and device usability support switching from alternative intraclass corticosteroids.

5) What type of R&D offers the best ROI for TA?

Formulation and administration improvements that produce measurable adherence or tolerability advantages, paired with trials that use endpoints relevant to reimbursement and guideline adoption.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. https://clinicaltrials.gov/
[2] U.S. Food and Drug Administration. Drug Approval Reports and Labeling Databases. https://www.fda.gov/drugs/drug-approvals-and-databases
[3] European Medicines Agency. Medicines overview and EPAR database. https://www.ema.europa.eu/